As payers struggle to cover high-priced pharmaceutical therapies in a year in which the first drug costing more than $1 million is expected to launch in the U.S., new payment models are emerging — including a “Netflix”-like subscription model in Louisiana for hepatitis C virus treatment — that could offer ways for patients to be treated without bankrupting the health care system.
- Datapoint, Medicare and Medicaid
- Abstract, Drug Benefits
- People on the Move
- Medicare and Medicaid
- Datapoint, Drug Benefits